Background: Most studies quantify IL-6 only at patient admission, a strategy that may not be appropriate to accurately predict the outcome or to guide treatment due to the dynamic inflammatory process occurring during infection with SARS-CoV-2. Objective: This study aimed to investigate the association between interleukin-6 serum level and severity of disease among pediatrics with covid-19. Patients and methods: A cross-sectional study was conducted on 130 children with COVID-19. All children were divided into4 groups according to WHO criteria as asymptomatic, which included 20 children, mild included that 60 cases, moderate that included 40 cases and severe, which included 10 cases. All cases were admitted to Benha Teaching Hospital, with a diagnosis of COVID-19 during the period study from February 2020 to December 2020. Results: Interleukin-6 serum level was significantly increased with severe than other severity features groups. ROC curve analysis showed that procalcitonin and interleukin-6 were the best markers for early prediction of severity of disuses among children with covid-19. The sensitivity of interleukin-6 was 87.9% and specificity was 63.5%, at AUC of 0.640 with cut-off of 7.41. Conclusion: Children at any age seem to be susceptible to COVID-19, and even though their symptoms are milder, they still present a diverse range of clinical presentations. Interleukin-6 was the best marker for determining the severity of disease among pediatrics with covid-19.